W. Bryan

MUNE as an endpoint in clinical trials

W. Bryan, 2003 .

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

Amy McKee, R. Pazdur, B. George, 2018, Clinical Cancer Research.

The state of gene therapies: the FDA perspective.

W. Bryan, D. Takefman, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Evaluation of optic neuritis following human papillomavirus vaccination

M. Kulldorff, R. Forshee, Lei Xu, 2017, Human vaccines & immunotherapeutics.

Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project

B. George, Yuan Xu, W. Bryan, 2022, Molecular therapy oncolytics.

Association of immune globulin intravenous and thromboembolic adverse events

S. Anderson, R. Forshee, D. Scott, 2017, American journal of hematology.

FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Ke Liu, Richard Pazdur, Xiaobin Lu, 2018, Clinical Cancer Research.

Evaluation of Guillain-Barré Syndrome among recipients of influenza vaccine in 2000 and 2001.

D. Burwen, L. La Voie, M. Braun, 2010, American journal of preventive medicine.